C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/00 (2006.01) A61K 31/135 (2006.01) A61K 31/34 (2006.01) A61K 31/365 (2006.01) A61K 31/45 (2006.01) A61K 31/495 (2006.01) G01N 33/48 (2006.01) G01N 33/50 (2006.01)
Patent
CA 2138123
The quest for anticancer drugs has been primarily directed at agents that interfere with cell replication, yet the basis for drug-induced cytotoxicity remains unsolved. In our previous studies we noted a relationship between a mitotic block and commit- ment to terminal differentiation in the murine Friend erythroleukemia (FEL) cell. Since anticancer drugs are known to often block cell cycle transit typically in G2/mitosis, a number of anticancer drugs with various modes of action were tested and it was found that they all committed FEL cells to differentiate. Furthermore, other G2/mitosis-blocking drugs were also effec- tive in inducing commitment. These results suggest (1) a casual relationship involving anticancer drugs, cell cycle block and differentiation (2) that the search for new anticancer drugs utilize a differentiation assay and include G2/mitosis-blocking agents.
Dinnen Richard D.
Ebisuzaki Kaney
Dinnen Richard D.
Ebisuzaki Kaney
Hill & Schumacher
Procyon Biopharma Inc.
LandOfFree
A novel in-vitro method of screening potential anticancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with A novel in-vitro method of screening potential anticancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and A novel in-vitro method of screening potential anticancer... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1825790